Mecobalamin
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Dementia With Vitamin B12 Deficiency
Conditions
Dementia With Vitamin B12 Deficiency
Trial Timeline
Mar 1, 2003 → —
NCT ID
NCT00165711About Mecobalamin
Mecobalamin is a approved stage product being developed by Eisai for Dementia With Vitamin B12 Deficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT00165711. Target conditions include Dementia With Vitamin B12 Deficiency.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00165711 | Approved | Completed |
Competing Products
20 competing products in Dementia With Vitamin B12 Deficiency
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| [18F]NAV4694 | Navidea Biopharmaceuticals | Phase 3 | 69 |
| AL001 + Placebo + Open label - AL001 | Alector | Phase 3 | 69 |
| AL001 | Alector | Phase 2 | 44 |
| ATH-1017 + Placebo | LeonaBio | Phase 2 | 44 |
| IGC AD1 + Placebo | IGC Pharma | Phase 1 | 25 |
| E2020 + Placebo | Eisai | Approved | 85 |
| ARICEPT | Eisai | Phase 3 | 77 |
| Rasagiline | Eisai | Phase 2 | 52 |
| Donepezil Hydrochloride | Eisai | Pre-clinical | 23 |
| donepezil hcl | Eisai | Phase 3 | 77 |
| Donepezil 5 mg + Donepezil 10 mg + Donepezil matched placebo | Eisai | Phase 3 | 77 |
| E2020 + E2020 | Eisai | Phase 2 | 52 |
| donepezil hydrochloride (Aricept) | Eisai | Approved | 85 |
| 3 mg Donepezil hydrochloride + 5 mg Donepezil hydrochloride + 10 mg Donepezil hydrochloride + Placebo | Eisai | Phase 2 | 52 |
| E2020 + E2020 | Eisai | Phase 3 | 77 |
| Irsenontrine + Placebo | Eisai | Phase 2 | 52 |
| E2020 | Eisai | Phase 2 | 52 |
| E2020 + Placebo | Eisai | Phase 3 | 77 |
| Donepezil Hydrochloride | Eisai | Phase 3 | 77 |
| Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochloride | Eisai | Approved | 85 |
Other Products from Eisai
MonteplaseApproved
85
E2020 + PlaceboApproved
85
Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVApproved
85
DonepezilApproved
85
Lemborexant (LEM) 5 mg (Z-Drug-mono cohort) + Lemborexant (LEM) 5 mg (SUV-mono cohort) + Lemborexant (LEM) 5 mg (SUV-combination cohort) + Lemborexant (LEM) 5 mg (RMT-combination cohort)Approved
85